

Supplementary Material

Ionic-liquid-based aqueous biphasic systems meet microfluidics: from antibodies to aptamers in prostate-specific antigen detection

Maria S. M. Mendes^{1,2}, Virginia Chu², Mara G. Freire¹, Francisca A. e Silva^{1*}, João P. Conde^{2,3*}

¹CICECO – Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Aveiro, Portugal

²Instituto de Engenharia de Sistemas e Computadores – Microsistemas e Nanotecnologias (INESC MN), Lisbon, Portugal

³Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

*To whom correspondence may be addressed. E-mail: francisca.silva@ua.pt; joao.conde@tecnico.ulisboa.pt

Table of contents

SI Tables

Table S1. Fluorescence intensity measurements obtained using an antibody-antibody immunoassay for PSA concentrations ranging from 0 to 25 ng·mL⁻¹ in PBS, human serum, ABS top phase (without serum), and ABS top phase after serum pretreatment. Data were used for the construction of sensitivity curves and the determination of the LoD (N/D = Not determined).

Table S2. Fluorescence intensity data showing the effect of aptamer concentration and pre-incubation with PSA on signal generation in the microfluidic aptamer-based immunoassay.

Table S3. Fluorescence intensity measurements obtained using an aptamer-based immunoassay for PSA concentrations ranging from 0 to 25 ng·mL⁻¹ in PBS, human serum, ABS top phase (without serum), and ABS top phase after serum pretreatment. Data were used for the construction of sensitivity curves and the determination of the LoD.

SI Tables

Table S1. Fluorescence intensity measurements obtained using an antibody-antibody immunoassay for PSA concentrations ranging from 0 to 25 ng·mL⁻¹ in PBS, human serum, ABS top phase (without serum), and ABS top phase after serum pretreatment. Data were used for the construction of sensitivity curves and the determination of the LoD (N/D = Not determined).

[PSA] (ng·mL ⁻¹)	Fluorescence Intensity (A.U.)			
	PBS	Human serum	ABS top phase	ABS top phase after serum pretreatment
0	12209 ± 1021	12549 ± 872	2551 ± 255	1962 ± 405
5	14140 ± 1480	N/D	3513 ± 664	2348 ± 391
10	14849 ± 654	N/D	4821 ± 783	2604 ± 566
15	17100 ± 550	N/D	5977 ± 452	3633 ± 215
20	20781 ± 1438	N/D	6876 ± 410	4215 ± 618
25	22393 ± 955	7115 ± 2192	7572 ± 782	4453 ± 547

Table S2. Fluorescence intensity data showing the effect of aptamer concentration and pre-incubation with PSA on signal generation in the microfluidic aptamer-based immunoassay.

[PSA] (ng·mL ⁻¹)	Fluorescence Intensity (A.U.)			
	5 uM + No incubation	5 uM + 30 min incubation	10 uM + No incubation	10 uM + 30 min incubation
0	1314 ± 224	618 ± 9	1030 ± 336	482 ± 106
25	3901 ± 216	4880 ± 634	2321 ± 460	9265 ± 467

Table S3. Fluorescence intensity measurements obtained using an aptamer-based immunoassay for PSA concentrations ranging from 0 to 25 ng·mL⁻¹ in PBS, human serum, ABS top phase (without serum), and ABS top phase after serum pretreatment. Data were used for the construction of sensitivity curves and the determination of the LoD.

[PSA] (ng·mL ⁻¹)	Fluorescence Intensity (A.U.)			
	PBS	Human serum	ABS top phase	ABS top phase after serum pretreatment
0	482 ± 106	3918 ± 186	714 ± 150	660 ± 153
5	1062 ± 390	4074 ± 94	1247 ± 119	1339 ± 124
10	1528 ± 246	4807 ± 379	1783 ± 202	2054 ± 293
15	3899 ± 303	6890 ± 385	3372 ± 383	2919 ± 97
20	5971 ± 576	8230 ± 478	4098 ± 345	3065 ± 153
25	9265 ± 467	9528 ± 142	5082 ± 104	3469 ± 225